Stomach Diseases  >>  cisplatin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT00150670: Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

Completed
3
300
Japan
TS-1 and cisplatin, TS-1
Taiho Pharmaceutical Co., Ltd.
Gastric Cancer
12/06
12/06
JCOG9912, NCT00142350: A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer

Completed
3
690
Japan
continuous infusion of 5-fluorouracil, combination of irinotecan and cisplatin, oral administration of S-1
Japan Clinical Oncology Group, Ministry of Health, Labour and Welfare, Japan, Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., LTD
Gastric Cancer
 
01/07
AVAGAST, NCT00548548: A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Checkmark In pts with gastric cancer
Jun 2014 - Jun 2014: In pts with gastric cancer
Checkmark P3 data (Gastric) - AVAGAST
May 2012 - May 2012: P3 data (Gastric) - AVAGAST
Checkmark Data-ASCO-GI
More
Completed
3
774
US
Bevacizumab, Capecitabine, Cisplatin, Placebo, 5-fluorouracil
Genentech, Inc., Hoffmann-La Roche, Chugai Pharmaceutical
Adenocarcinoma
11/09
11/13
ToGA, NCT01041404 / 2005-000387-39: Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Checkmark From ToGA trial in gastric cancer
May 2015 - May 2015: From ToGA trial in gastric cancer
Checkmark HER2 screening data from ToGA trial
Jul 2014 - Jul 2014: HER2 screening data from ToGA trial
Checkmark QoL data
More
Completed
3
584
Japan, Europe, RoW
Trastuzumab, Herceptin, Fluorouracil, 5-FU, Cisplatin, Capecitabine, Xeloda
Hoffmann-La Roche, Chugai Pharmaceutical
Gastric Cancer
06/10
06/10
NCT00887822: A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer

Checkmark Data-ASCO-GI
Jan 2012 - Jan 2012: Data-ASCO-GI
Completed
3
202
RoW
Bevacizumab, Avastin, Placebo, Capecitabine, Xeloda, Cisplatin
Hoffmann-La Roche
Gastric Cancer
05/11
08/14
NCT00811447: Taxotere New Indication - Gastric Cancer Treatment Registration Trial

Completed
3
243
RoW
5-fluorouracil, Cisplatin, Docetaxel
Sanofi
Stomach Neoplasms
06/12
06/12
RILOMET-1, NCT01697072 / 2011-004923-11: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Terminated
3
609
US, Canada, Europe, RoW
Rilotumumab, AMG102, Placebo, sterile protein-free solution, Epirubicin, Ellence, Pharmorubicin PFS, Pharmorubicin RDF, Cisplatin, Platinol, Platinol-AQ, Capecitabine, Xeloda
Amgen
Gastric Cancer
11/14
08/15
NCT01450696 / 2011-001526-19: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Terminated
3
296
US, Europe, RoW
Capecitabine, Cisplatin, Herceptin, Trastuzumab
Hoffmann-La Roche
Gastric Cancer
02/15
08/15
RILOMET-2, NCT02137343: A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer

Checkmark For gastric cancer [Development discontinued in Gastric cancer]
Nov 2014 - Nov 2014: For gastric cancer [Development discontinued in Gastric cancer]
Terminated
3
34
Japan, RoW
Rilotumumab, AMG102, Placebo, Cisplatin, Platinol, Platinal-AQ, Capecitabine, Xeloda
Amgen
Gastric Cancer
06/15
06/15
CRITICS, NCT00407186 / 2006-004130-32: Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer

Active, not recruiting
3
788
Europe
cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine
Dutch Colorectal Cancer Group, The Netherlands Cancer Institute, Roche Pharma AG
Gastric Cancer
12/18
12/25
NCT01824459: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

Completed
3
576
RoW
S-1, Oxaliplatin, Cisplatin
Sun Yat-sen University, Taiho Pharmaceutical Co., Ltd.
Gastric Cancer
12/18
12/18
NCT00290966: Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer

Completed
2/3
610
US, RoW
XRP6976
Sanofi
Stomach Neoplasm
 
05/03

Download Options